Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study
Background/Aim The aim of this study was to compare the therapeutic efficacy of ablation and surgery in solitary hepatocellular carcinoma (HCC) measuring ≤5 cm with a large HCC cohort database. Methods The study included consecutive 2,067 patients with solitary HCC who were treated with either ablat...
Main Authors: | Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, Hidenori Toyoda, Toshifumi Tada, Kunihiko Tsuji, Toru Ishikawa, Takeshi Hatanaka, Ei Itobayashi, Koichi Takaguchi, Akemi Tsutsui, Atsushi Naganuma, Satoshi Yasuda, Satoru Kakizaki, Akiko Wakuta, Shohei Shiota, Masatoshi Kudo, Takashi Kumada |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Liver Cancer Association
2024-03-01
|
Series: | Journal of Liver Cancer |
Subjects: | |
Online Access: | http://www.e-jlc.org/upload/pdf/jlc-2023-09-11.pdf |
Similar Items
-
Attempt to establish prognostic predictive system for hepatocellular carcinoma using artificial intelligence for assistance with selection of treatment modality
by: Atsushi Hiraoka, et al.
Published: (2023-05-01) -
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis
by: Kazuya Kariyama, et al.
Published: (2020-10-01) -
Fibrosis-3 Index: A New Score to Predict Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Without Age as a Factor
by: Kazuya Kariyama, et al.
Published: (2022-01-01) -
The prognosis of elderly patients with hepatocellular carcinoma: A multi‐center 19‐year experience in Japan
by: Takeshi Hatanaka, et al.
Published: (2023-01-01) -
Letter regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study”
by: Takeshi Hatanaka, et al.
Published: (2024-03-01)